Stifel Nicolaus Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Hold

August 16, 2012 12:27 PM EDT Send to a Friend
Get Alerts IDIX Hot Sheet
Price: $24.50 --0%

Rating Summary:
    2 Buy, 14 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade IDIX Now!
Join SI Premium – FREE
Stifel Nicolaus upgraded Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) from Sell to Hold, with shares under heavy pressure after the company announced that hepatitis C drug IDX184 has been placed on partial clinical hold by the FDA due to a serious cardiac-related adverse event.

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

Shares of Idenix Pharmaceuticals are down 30 percent, but off the day's lows.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Upgrades

Related Entities

Stifel Nicolaus

Add Your Comment